News | Stents Peripheral | March 16, 2017

Gore Tigris Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a dual-component stent with a fluoropolymer/nitinol design. The device, which gained CE Mark approval in 2011, is a third-generation, self-expanding stent that was designed explicitly to improve anatomical conformability with the natural movement of the knee when treating peripheral artery disease (PAD).

The newly-approved Gore Tigris uses a dual component structure, made from a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections. The stent has been designed to weather biomechanical forces (extension, compression, flexion and torsion) without fractures, even in the most complex anatomies, namely in the superficial femoral artery (SFA) and popliteal arteries. In the U.S. clinical study that supported U.S. Food and Drug Administration (FDA) approval, the stent was found to have zero fractures at 12 months, while the control arm devices experienced a 27 percent fracture rate at the same time point.

The Gore Tigris also features the company’s CBAS Heparin Surface, a heparin bonding technology designed to resist thrombus formation, a problem common in both bare metal and drug-eluting stents. End-point covalent bonding keeps heparin anchored to the stent surface, while the bioactive site remains free to interact with the blood to help prevent clotting.

The evolution of peripheral stenting over the past decade has allowed for broader adoption of endovascular therapy for treating PAD. When physicians began placing stents in the SFA, they were limited by first-generation stent designs that had longitudinal metal connections that led to arterial stiffening, high fracture rates and poorer clinical outcomes. Improvements in second-generation devices introduced helical interconnections to improve flexibility; however, their success in high flexion vessels, like the distal SFA and proximal popliteal artery, was still limited. The introduction of third-generation stents, including the Gore Tigris, allow for better adherence in some of the more intricate vessels in the body.

PAD is prevalent in older populations, a rapidly growing demographic in developed countries. In Canada alone, as many as 800,000 people suffer from some form of PAD. The disease can manifest in mild symptoms such as chronic leg pain, and more serious complications include poor wound healing, increased risk of stroke, and amputation. Endovascular treatment, via angioplasty and stenting of a blocked artery, is designed to treat PAD without the complications that can accompany open surgery.

For more information: www.goremedical.com

Related Content

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
Sponsored Content | Videos | Hemodynamic Support Devices| March 21, 2017
The Abiomed Impella percutaneous ventricular assist devices (pVAD) offer between 2.5 and 5 liters of flow per minute
Technology | Guidewires| March 20, 2017
March 20, 2017 — Teleflex Inc. recently announced 510(k) clearance by the U.S.
iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Catheters| March 20, 2017
March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR)
Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals| March 20, 2017
March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology annu
Michael Reardon, SURTAVI, TAVR equals surgery in intermediate risk patients

SURTAVI Trial principal investigator Michael Reardon presents the data as a lake-breaker at ACC 2017. 

News | Heart Valve Technology| March 17, 2017 | Dave Fornell
March 17, 2017 - Transcatheter aortic valve replacement (TAVR) was found to be noninferior to surgical aortic valve r
Siemens Healthineers, ACC 2017, syngot CTO Guidance, Compressed Sensing Cardiac Cine
News | Cardiac Imaging| March 16, 2017
During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in...
Overlay Init